MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs
Athalia R. Pyzer, David Avigan(Beth Israel Deaconess Medical Center), Poorvi Somaiya(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Rebecca Karp Leaf(California University of Pennsylvania), Leandra Cole(Beth Israel Deaconess Medical Center), Eleni Anastasiadou(Sapienza University of Rome), Maxwell Coll, Hasan Rajabi(Harvard University), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Arie Apel(Tel Aviv University), Donald Küfe(Dana-Farber Cancer Institute), Myrna Nahas, Salvia Jain(Broad Institute), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Kristen Palmer(Beth Israel Deaconess Medical Center), Ashujit Tagde(Dana-Farber Cancer Institute), Abigail Washington(Beth Israel Deaconess Medical Center), Frank J. Slack(Beth Israel Deaconess Medical Center)
Cited by 2
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
The <i>let-7</i> MicroRNA Represses Cell Proliferation Pathways in Human Cells
|Cancer Research|2007|1.2k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k